Holen Sie sich die Stockscreener-App
0.6942
2.65%
0.0179
Handel nachbörslich:
.71
0.0158
+2.28%
Schlusskurs vom Vortag:
$0.6763
Offen:
$0.6801
24-Stunden-Volumen:
1.50M
Relative Volume:
1.71
Marktkapitalisierung:
$62.87M
Einnahmen:
$5.12M
Nettoeinkommen (Verlust:
$-67.00M
KGV:
-1.3145
EPS:
-0.5281
Netto-Cashflow:
$-38.94M
1W Leistung:
-8.77%
1M Leistung:
-21.77%
6M Leistung:
-90.37%
1J Leistung:
-87.67%
1-Tages-Spanne:
$0.6482
$0.7381
1-Wochen-Bereich:
$0.6109
$0.7989
52-Wochen-Spanne:
$0.6109
$11.41
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Firmenname
Verrica Pharmaceuticals Inc
Sektor
Branche
Telefon
484-453-3300
Adresse
10 NORTH HIGH STREET, WEST CHESTER, PA
Vergleichen Sie VRCA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
0.6942 | 62.87M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | Hochstufung | Needham | Hold → Buy |
| 2023-03-22 | Eingeleitet | Jefferies | Buy |
| 2023-02-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-06-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-24 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-24 | Eingeleitet | Needham | Buy |
| 2019-02-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten
Verrica Pharmaceuticals Reports Progress on Molluscum Treatment and Pipeline Development - MSN
Verrica reports rise in YCANTH applicator units in Q4 By Investing.com - Investing.com South Africa
Verrica reports rise in YCANTH applicator units in Q4 - Investing.com
Verrica Provides Business and Operational Update - GlobeNewswire
Verrica Pharma's YCANTH Sales Surge in Q4; Plans Game-Changing Single Applicator Launch for 2025 - StockTitan
GLP-1 Receptor Agonist Market Is Booming Worldwide 2024-2031:Verrica Pharmaceuticals,AbbVie Inc,Glenmark - EIN News
Verition Fund Management LLC Acquires New Holdings in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Verrica Pharmaceuticals stock hits 52-week low at $0.7 By Investing.com - Investing.com Canada
Verrica Pharmaceuticals stock hits 52-week low at $0.7 - Investing.com
Verrica Pharmaceuticals' SWOT analysis: stock faces headwinds amid strategic shift - Investing.com
Verrica Pharmaceuticals' SWOT analysis: stock faces headwinds amid strategic shift By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Inc. Appoints David Zawitz as Chief Operating Officer - Marketscreener.com
GLP-1 Receptor Agonist Market Is Booming Worldwide 2024-2031: Novan Inc., Verrica Pharmaceuticals, AbbVie - EIN News
Verrica Pharmaceuticals Grants Stock Option to New COO David Zawitz - MSN
PERCEPTIVE ADVISORS LLC Increases Stake in Verrica Pharmaceutica - GuruFocus.com
Verrica Pharmaceuticals appoints new COO By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals appoints new COO - Investing.com India
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Verrica Pharmaceuticals Appoints New Chief Operating Officer - TipRanks
Verrica's partner Torii seeks Japan NDA for skin treatment By Investing.com - Investing.com Canada
New Drug Application Submitted in Japan for Verrica Pharmaceuticals’ TO-208 - MyChesCo
Verrica's partner Torii seeks Japan NDA for skin treatment - Investing.com India
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan - The Manila Times
Verrica Pharmaceuticals Announces that Development Partner - GlobeNewswire
Verrica's Partner Files NDA in Japan for Breakthrough Molluscum Treatment, Targeting 1.6M Patient Market - StockTitan
Verrica Pharmaceuticals (FRA:1NE) Debt-to-Revenue : N/A (As of Sep. 2024) - GuruFocus.com
Virpax Pharmaceuticals Announces Positive Results in Study for Long-Lasting Pain Relief Formulation - MSN
Common Warts Pipeline Insights 2024: Therapies, Clinical - openPR
West Chester-based Verrica Pharmaceuticals Expects to Raise $42 Million in Public Stock Offering - VISTA.Today
Latham & Watkins Advises on Verrica Pharmaceuticals Inc.’s Public Offering - Latham & Watkins LLP
Chester County firm expects to raise $42M after trimming staff and naming new CEO - The Business Journals
Verrica Pharmaceuticals stock dips after pricing $42M securities offering - MSN
Verrica Prices of $42 Million Public Offering - citybiz
VRCAVerrica Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Verrica Announces Pricing of $42.0 Million Public Offering - GlobeNewswire
Verrica Pharmaceuticals Raises $42M Through Public Offering of Shares and Warrants | VRCA Stock News - StockTitan
Verrica Pharmaceuticals announces proposed public offering - MSN
Form 424B5 Verrica Pharmaceuticals - StreetInsider.com
Verrica Announces Proposed Public Offering - The Manila Times
Verrica Pharmaceuticals Announces Public Offering of Stock and Warrants with Jefferies | VRCA Stock News - StockTitan
Verrica Pharmaceuticals Reports Q3 2024 Financials and Restructuring Plans - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Verrica Pharmaceuticals' SWOT analysis: navigating challenges in dermatology stock - Investing.com
Verrica Pharmaceuticals' SWOT analysis: navigating challenges in dermatology stock By Investing.com - Investing.com UK
Q1 Earnings Forecast for VRCA Issued By HC Wainwright - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to “Neutral” at HC Wainwright - Defense World
Verrica downgraded to sector perform by RBC Capital - MSN
Verrica Pharmaceuticals’ (VRCA) Hold Rating Reaffirmed at Needham & Company LLC - Defense World
Biotech Alert: Searches spiking for these stocks today - TipRanks
Finanzdaten der Verrica Pharmaceuticals Inc-Aktie (VRCA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):